Evidence map›Paper›PMID 37827838›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A Bundschuh and 5 more

Erratum issuedOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Future of radiotheranostics.BMJ oncology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Current oncology (Toronto, Ont.) · 2024
    Review
  8. Sequential and Combination Therapies ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 3 countries.

Kambiz RahbarDepartment of Nuclear Medicine, University of Münster Medical Center, Münster, Germany; rahbar@uni-muenster.de.
Markus EsslerDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Matthias EiberDepartment of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Christian la FougèreDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany.
Vikas PrasadDepartment of Nuclear Medicine, University of Ulm, Ulm, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, German Cancer Consortium University Hospital Essen, Essen, Germany.
Philipp RassekDepartment of Nuclear Medicine, University of Münster Medical Center, Münster, Germany.
Ergela HasaDepartment of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Helmut DittmannDepartment of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, Germany.
Ralph A BundschuhDepartment of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
Kim M PabstDepartment of Nuclear Medicine, German Cancer Consortium University Hospital Essen, Essen, Germany.
Milena KurtineczBayer HealthCare Pharmaceuticals, Whippany, New Jersey.
Anja SchmallBayer Consumer Care, Basel, Switzerland; and.
Frank VerholenBayer Consumer Care, Basel, Switzerland; and.
Oliver SartorTulane Cancer Center, Tulane Medical School, New Orleans, Louisiana.
Bayer (Switzerland) · CHTechnical University of Munich · DEUniversity Hospital Bonn · DEBayer (United States) · USDeutschen Konsortium für Translationale Krebsforschung · DEEssen University Hospital · DETulane Medical Center · USUniversität Ulm · DEUniversity Hospital Münster · DEUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Prostatic Neoplasms, Castration-ResistantRadiumDipeptidesHeterocyclic Compounds, 1-RingHumansLutetiumMaleProstateProstate-Specific AntigenRadiopharmaceuticalsRetrospective StudiesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstate-Specific AntigenRadiopharmaceuticalsRadium177Lu-PSMA223Rametastatic castration-resistant prostate cancerreal-world practicetargeted α-therapy

Identifiers

PMID37827838
PMCPMC10690117
OpenAlexW4387568235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.